Bemarituzumab is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Gastroesophageal (GE) Junction Carcinomas. According to Globaldata, it is involved in 12 clinical trials, of which 6 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Bemarituzumabs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Bemarituzumab is expected to reach an annual total of $570 mn by 2037 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bemarituzumab Overview
Bemarituzumab [FPA-144] is under development for the treatment of solid tumors such as gastric cancer, squamous non-small cell lung cancer, gastroesophageal cancer, transitional cell carcinoma, lymphoma, bladder cancer, head and neck squamous cell carcinoma, lung adenocarcinoma, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma, triple-negative breast cancer, pancreatic ductal adenocarcinoma, intrahepatic cholangiocarcinoma, colorectal adenocarcinoma, ovarian epithelial cell carcinoma, endometrial adenocarcinoma and cervical carcinoma. The drug candidate is administered through intravenous route. It is a humanized monoclonal antibody directed against a splice form of fibroblast growth factor receptor 2 (FGFR2). It is a targeted immunotherapy for FGFR2b-overexpressing tumors and designed to recruit tumor-killing NK cells into the tumor microenvironment. The drug candidate is developed based on Potelligent CHOK1SV technology. Potelligent CHOK1SV, combines the advantages of GS Gene Expression System with the glyco-engineered technology.
It was also under development for the treatment of breast cancer.
Amgen Overview
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines for the treatment of cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders and nephrology conditions. The company analyzes the difficulties of disease and understands the fundamentals of human biology to develop products harnessing advanced human genetics. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, the Americas and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
The company reported revenues of (US Dollars) US$28,190 million for the fiscal year ended December 2023 (FY2023), an increase of 7.1% over FY2022. In FY2023, the companys operating margin was 28.8%, compared to an operating margin of 36.6% in FY2022. In FY2023, the company recorded a net margin of 23.8%, compared to a net margin of 24.9% in FY2022.
The company reported revenues of US$7,447 million for the first quarter ended March 2024, a decrease of 9.1% over the previous quarter.
For a complete picture of Bemarituzumabs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
